Psyched: LSD Microdosing For Depression, DMT For Anxiety, MDMA Octopuses And More
Portfolio Pulse from Lara Goldstein
MindBio Therapeutics has been granted approval to begin the world's first Phase 2a take-home LSD microdosing trial for Major Depressive Disorder. Cybin Inc. announced the first group of participants have been dosed with its proprietary deuterated DMT molecule, CYB004, in an ongoing Phase 1 trial. Positive long-term follow-up data from Sunstone Therapies’ Phase 2 study assessing COMPASS Pathways’ synthetic psilocybin COMP360 in cancer patients with MDD has been released.

May 31, 2023 | 3:59 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
AdvisorShares Psychedelics ETF (PSIL) has shown a somewhat constant trend in its weekly performance.
The weekly performance of AdvisorShares Psychedelics ETF (PSIL) has shown a somewhat constant trend, indicating that there may not be any significant short-term impact on its stock price based on the news.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 60
POSITIVE IMPACT
COMPASS Pathways' synthetic psilocybin COMP360 showed positive long-term follow-up data in a Phase 2 study for cancer patients with Major Depressive Disorder.
The positive long-term follow-up data from the Phase 2 study assessing COMPASS Pathways' synthetic psilocybin COMP360 in cancer patients with Major Depressive Disorder indicates potential for the treatment's effectiveness and may positively impact the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 80
POSITIVE IMPACT
Cybin Inc. announced the first group of participants have been dosed with its proprietary deuterated DMT molecule, CYB004, in an ongoing Phase 1 trial for anxiety treatment.
Cybin Inc.'s announcement of the first group of participants being dosed with its proprietary deuterated DMT molecule, CYB004, in an ongoing Phase 1 trial for anxiety treatment indicates progress in the company's clinical development, which may positively impact its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80